As of 2025-05-15, the Intrinsic Value of APT Medical Inc (688617.SS) is 222.77 CNY. This 688617.SS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 414.30 CNY, the upside of APT Medical Inc is -46.20%.
The range of the Intrinsic Value is 164.59 - 356.59 CNY
Based on its market price of 414.30 CNY and our intrinsic valuation, APT Medical Inc (688617.SS) is overvalued by 46.20%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 164.59 - 356.59 | 222.77 | -46.2% |
| DCF (Growth 10y) | 347.14 - 767.33 | 474.95 | 14.6% |
| DCF (EBITDA 5y) | 511.35 - 662.02 | 618.11 | 49.2% |
| DCF (EBITDA 10y) | 858.12 - 1,217.16 | 1,080.56 | 160.8% |
| Fair Value | 169.66 - 169.66 | 169.66 | -59.05% |
| P/E | 191.67 - 262.77 | 231.34 | -44.2% |
| EV/EBITDA | 105.50 - 234.70 | 170.66 | -58.8% |
| EPV | 27.43 - 33.60 | 30.51 | -92.6% |
| DDM - Stable | 60.74 - 179.86 | 120.30 | -71.0% |
| DDM - Multi | 183.11 - 415.65 | 253.59 | -38.8% |
| Market Cap (mil) | 40,220.24 |
| Beta | 0.65 |
| Outstanding shares (mil) | 97.08 |
| Enterprise Value (mil) | 39,633.07 |
| Market risk premium | 6.13% |
| Cost of Equity | 9.61% |
| Cost of Debt | 5.00% |
| WACC | 9.60% |